What Is Anxiety and How It Affects Your Brain and Body

Share this post:

LinkedIn
Facebook
X
Reddit
WhatsApp
Print

Anxiety is a state of heightened alertness marked by fear, tension, worry and physical arousal that prepares you to respond to a possible threat. It affects both the brain and the body by activating stress circuits, shifting attention toward danger and changing heart rate, breathing, muscle tone and hormone release.

In medical terms, anxiety is a normal protective response that becomes a health concern when it appears too often, feels too intense, lasts too long or interferes with daily functioning. You may feel it as nervous anticipation, racing thoughts, restlessness, dread or a sense that something bad is about to happen. You may also feel it through the body as chest tightness, stomach upset, sweating, trembling, dizziness, muscle tension or a pounding heartbeat.

Anxiety begins in brain systems that detect threat and trigger survival responses. Once those systems activate, your nervous system shifts into a state designed for quick action. Attention narrows. The body prepares for movement. Digestion slows. Breathing changes. This is why anxiety feels both mental and physical at the same time.

For many people, anxiety rises in response to real pressure such as conflict, financial strain, illness, uncertainty or major life change. For others, the response appears with little immediate danger. The brain may react to memory, anticipation, body sensations or learned fear patterns. In both cases, the same stress machinery is involved. The main difference lies in intensity, duration and how much the response disrupts your life.

The biological purpose of the fight or flight response

The fight or flight response is a fast survival system. It developed to help you react to danger with speed. When the brain detects a threat, signals move through stress pathways that prepare the body to defend itself or escape. This response can start before you have fully thought through the situation.

A key brain region involved in threat detection is the amygdala. It scans incoming information for emotional salience, especially signs of danger. When the amygdala reads something as threatening, it can send rapid signals that activate the hypothalamus. The hypothalamus then directs the autonomic nervous system and the hormonal stress response.

The autonomic nervous system has two major branches that are relevant here. The sympathetic branch increases activation. The parasympathetic branch supports rest, digestion and recovery. During acute anxiety, sympathetic activity rises. Adrenaline and related stress chemicals increase. Your heart beats faster. Blood flow shifts toward large muscles. Pupils may widen. Breathing becomes quicker. Sweat production rises. Pain sensitivity can drop for a short period. These changes prepare you for immediate action.

This reaction is useful in truly dangerous situations. If a car swerves toward you, the brain does not pause for slow reflection. It prioritizes rapid movement. The same system can also activate in response to less direct threats such as public speaking, conflict, health fears or uncertainty about the future. Your body can react strongly even when the threat is social, symbolic or anticipated rather than physical.

The fight or flight response also has a time course. First comes rapid activation through the autonomic nervous system. Then comes a slower hormonal phase through the stress axis that links the hypothalamus, pituitary gland and adrenal glands. This system releases cortisol, a hormone that helps mobilize energy and keep the body in a ready state. In short bursts, cortisol helps with adaptation. Repeated elevation can contribute to sleep problems, irritability, concentration trouble and persistent tension.

Anxiety can also trigger freezing. Some people think only in terms of fighting or fleeing, but the brain can also respond with immobility, shutdown or difficulty acting. You may feel stuck, blank or detached. This still belongs to the larger threat response system.

How everyday stress differs from a clinical disorder

Everyday stress is common and often proportional to a real demand. You may feel tense before an interview, alert during a deadline or nervous ahead of an exam. The response rises around the event and settles afterward. You can still work, make decisions and recover.

A clinical anxiety disorder involves a stronger and more persistent pattern. Symptoms can appear without a clear trigger, remain active long after the trigger passes or spread across many parts of life. The fear response may become hard to regulate and daily functioning may suffer.

Several factors help distinguish routine stress from a disorder.

One factor is duration. Brief tension during a difficult week is common. Anxiety that lasts for months and keeps returning in a similar pattern points to a deeper issue.

Another factor is intensity. Mild nervousness can be uncomfortable but manageable. Clinical anxiety can produce severe physical symptoms, repeated panic, strong avoidance or constant mental preoccupation.

Another factor is impairment. Anxiety becomes clinically significant when it disrupts sleep, work, school, relationships, travel, eating, concentration or routine tasks. You may start avoiding stores, meetings, phone calls, driving, crowds or social interaction. You may seek reassurance again and again without lasting relief.

Another factor is mismatch between response and trigger. The nervous system may react as if the danger is extreme even when the situation is objectively low risk. This mismatch can happen in panic disorder, social anxiety disorder, generalized anxiety disorder, phobia related conditions and trauma related states.

Common signs that anxiety may be crossing into disorder

You may notice a pattern like this

  • worry that feels hard to stop
  • panic episodes with chest discomfort, dizziness or shaking
  • sleep disruption caused by racing thoughts
  • muscle tension, jaw clenching or headaches
  • stomach symptoms linked to fear or anticipation
  • repeated avoidance of situations that feel unsafe
  • constant scanning for danger, symptoms or social judgment
  • fatigue from staying mentally on guard

A clinical disorder does not mean weakness or poor coping. It reflects a stress system that has become overactive, highly conditioned or difficult to regulate. Genetics, past experiences, temperament, trauma, medical illness, sleep loss and substance use can all affect this process.

Diagnosis also depends on pattern, severity and context. A licensed clinician looks at symptom clusters, duration and functional impact. This helps separate temporary strain from a condition that calls for active treatment.

The chemical mechanics of an anxious brain

An anxious brain relies on rapid signaling between brain regions, nerves and chemical messengers. These messengers include neurotransmitters and hormones that shape arousal, attention, memory and bodily activation.

Adrenaline is one of the fastest acting chemicals in acute anxiety. It helps drive the pounding heart, shaky hands and urgent feeling that often come with panic or fear. It prepares the body for action within seconds.

Cortisol works on a slightly longer time scale. It helps keep the body mobilized during stress. When stress becomes chronic, cortisol patterns can become dysregulated. This can contribute to poor sleep, low frustration tolerance, fatigue and trouble focusing.

Several neurotransmitters also play major roles.

GABA helps calm neural activity. Lower inhibitory control in certain circuits can make the brain more reactive and less able to settle after a threat signal.

Glutamate is the main excitatory neurotransmitter. It supports signaling, learning and memory. Excessive excitatory tone in stress related circuits can raise arousal and strengthen fear learning.

Serotonin affects mood, threat processing, impulse control and emotional regulation. Changes in serotonin signaling have been linked to anxiety symptoms in many people.

Norepinephrine supports vigilance and alertness. High activity in this system can contribute to hyperarousal, scanning and a sense of internal alarm.

Dopamine also plays a part, especially in motivation, salience and reinforcement learning. In anxiety states, the brain may assign too much salience to feared outcomes or internal sensations.

Brain circuits involved in anxiety

The amygdala helps detect threat and attach emotional significance to incoming information. The prefrontal cortex supports planning, judgment and regulation. The hippocampus helps with memory and context. When anxiety is high, communication among these areas can shift.

The amygdala may react strongly to cues that feel threatening. The prefrontal cortex may have less regulatory control during high arousal. The hippocampus may link present situations to stored fear memories. This can make a harmless cue feel dangerous because it resembles an earlier experience or predicted outcome.

This process helps explain why anxiety can feel automatic. The brain is using learned associations, body signals and rapid chemical messaging before deliberate reasoning fully catches up.

How fear learning becomes persistent

The brain learns from repetition. If panic happens in a grocery store, your brain may start pairing that location with danger. If you then avoid the store, the brain does not get a chance to relearn safety in that setting. The fear pathway stays strong.

The same thing can happen with body sensations. A fast heartbeat after exercise can be misread as danger if you have had panic before. The sensation itself becomes a trigger. This is one reason anxiety can spread from one event into a broader pattern.

These learned loops involve neuroplasticity, which refers to the brain’s capacity to change through repeated experience. Fear pathways can strengthen through repeated activation. They can also shift through treatment, new learning and repeated corrective experiences. That principle sits under many forms of therapy and current research into brain health and mental recovery.

As research continues to examine anxiety at the level of circuits, neurotransmitters and learned responses, we at Rose Hill Life Sciences view brain health and mental recovery through the lens of safely rewiring these chemical mechanics. We are a psychedelic research organization specializing in the production and research of Psilocybe cubensis, operating at the intersection of science and therapeutic integration, and based in Massachusetts.

Disclaimer: The information in this article is for educational and informational purposes only and does not constitute medical advice.

You May Also Like

Adam Goodman

Advisor

Adam is a seasoned entrepreneur with a wealth of experience in spearheading real estate development and management endeavors. His focus primarily lies in land development, where he orchestrates the intricate tapestry of planning and zoning entitlements, while meticulously overseeing all facets of engineering and architectural design, leasing, construction, and financing.

With a national reach spanning 23 states and encompassing over 250 properties, totaling more than 6 million square feet, Adam’s proficiency in navigating the complexities of the industry is evident.

Beyond real estate, Adam’s endeavors extend into the realm of alternative investments, boasting successful ventures in healthcare, professional sports franchises, financial services, diverse agricultural platforms, and the stewardship of local restaurants.

 

Rotem Petranker, PhD, Psychology

Psychedelic Researcher

Rotem Petranker is a psychedelics researcher with a particular emphasis on microdosing, therapy, research methods and research ethics. He earned his BSc from the University of Toronto, his Master’s degree from York University, and his PhD from McMaster University.

As part of my research, I have gained extensive expertise in navigating the regulatory landscapes of Health Canada and the FDA and a strong background in designing rigorous clinical trial research methodologies. 

I founded the Canadian Centre for Psychedelic Science in 2018, established the Psychedelic Science Research Program at the University of Toronto in 2019, and, more recently, ran the largest clinical trial to date on the effectiveness of microdosing psilocybin for Major Depressive Disorders. I have published many papers on microdosing, including some of the largest samples in the literature and some that have set standards for performing psychedelic research.

Kevin Bourke

Chief Commercial Officer

Kevin Bourke is a dynamic executive and strategic planner whose career spans over two decades of crafting and elevating world-class Jamaican brands and transformational experiences on the global stage. With a keen understanding of culture, identity, and international markets, he has played a pivotal role in shaping some of Jamaica’s most iconic names — including Appleton Estate Rum, Chris Blackwell’s Rum, and Usain Bolt’s Tracks & Records — bringing them from local roots to international acclaim. His leadership and vision have also been instrumental in major cultural movements such as Fiction and the internationally recognized TmrwTday Wellness Festival.

An innovator at heart, Mr. Bourke seamlessly blends brand strategy with deep cultural resonance. His ability to connect with diverse audiences has established these brands not only as commercial successes but as symbolic ambassadors of Jamaican excellence, fortifying the island’s influence in beverage, music, lifestyle, and experiential sectors.

In recent years, Kevin has steered his strategic acumen toward the cutting-edge psilocybin and wellness industry, becoming a co-founder and Chief Marketing and Branding Officer of Rose Hill, Jamaica’s leading cultivator, exporter, and innovator of psilocybin products and experiences. Through ventures like ONE Retreats, he has helped craft safe, guided psychedelic-assisted healing programs that attract participants from around the world seeking deep personal transformation, including military veterans and international wellness seekers.

Kevin’s impact extends beyond business into industry shaping and policy, as he sits on the Jamaica Psilocybin Mushroom Industry Technical Committee (under the Bureau of Standards) — a pivotal body that is formalizing guidelines and regulatory standards for the emerging legal psilocybin sector in Jamaica. His presence on this committee underscores his leadership role in ensuring the industry’s integrity, safety, and sustainable growth.

Highly regarded for his extensive network throughout Jamaica and internationally, Kevin remains passionately committed to advancing ethical, high-integrity product development and customer-centric experiences at every level. His dedication is driven not only by professional achievement but by a deep vision for human well-being, cultural celebration, and the global evolution of plant-based healing.

Jama Pitman

Regulatory Strategy

Jama Pitman is a seasoned biopharmaceutical executive with extensive expertise in global drug development and commercialization. With over two decades of experience, she has contributed to the development of groundbreaking therapies across oncology, rare diseases, and antivirals. As a strategic leader, she has successfully transitioned companies from private to public markets, navigated complex M&A transactions, and driven innovative drug approvals.

Jama has held executive roles in leading organizations, including Deciphera Pharmaceuticals, where she played a pivotal role in scaling operations from a small, privately held biotech company to a global, multi-product company acquired for $2.4 billion. She brings exceptional skills in regulatory affairs, portfolio management, quality assurance, and clinical operations, longside a proven track record of fostering inclusivity and mentorship within her teams.

Currently, as the founder of JP BioPharma Consulting, Jama advises biopharma and tech companies on accelerating drug development and achieving corporate goals. Her collaborative and forward-thinking approach aligns seamlessly with Rose Hill’s mission to advance transformative therapies in mental health and beyond.

Education: B.Sc. in Microbiology, University of New Hampshire.

Notable Achievements: Contributed to the development of multiple FDA-approved therapies, including QINLOCK® for gastrointestinal stromal tumors.

Domenic Suppa

Chief Operating Officer

Domenic is co-founder and the Operations Chief of Rose Hill Health Holdings.

He has been working as a Cannabis technology and operations veteran with more than 11 years’ experience as a senior executive in an operationally complex, and highly regulated industry.

His introduction and entrance into the Cannabis sector started in 2010 with a seed investment into a Denver-based vertically integrated cannabis company called, Evolab. He served as C.O.O. for 5 years from 2013-2018, through the eventual acquisition by Harvest Health and Recreation (HARV: CSE).

Domenic moved on to be acting COO of the manufacturing division for Supreme Cannabis (CSE: FIRE) and supported the acquisition of BLISSCO (CSE: BLISS, a BC-based cannabis manufacturer). Domenic has worked with high-profile national cannabis brands including KKE, and Monogram, and retail brands in MA Native Sun, Terps, and Tilt. Domenic is a proven leader and team builder; his previous experiences have all been with early-stage and growth equity enterprises.

He has refined and evolved his leadership roles, including his team-building skills. He is a value creator. Domenic is a firm believer in training and continuous development. He excels in employing practices, tools, and methodologies designed to achieve maximum process efficiency while minimizing waste and delays.

 

Burton J. Tabaac

Clinical Development

Dr. Burton J. Tabaac, MD, FAHA, brings a wealth of expertise in neurology and stroke rehabilitation to Rose Hill. As an Associate Professor and Section Chief of Neurology at The University of Nevada’s Reno School of Medicine, and Medical Director of Stroke at Carson Tahoe Health, Dr. Tabaac has been at the forefront of innovative neurological treatments.

A graduate of the prestigious cerebrovascular neurology fellowship program at The Johns Hopkins University Hospital, Dr. Tabaac’s accolades include being a three-time recipient of The Arnold P. Gold Foundation’s Humanism and Excellence in Teaching Award and induction into the Alpha Omega Alpha Honor Medical Society.

He recently published an eight-part paper in the American Journal of Therapeutics reviewing psychedelics as therapeutics for primary care clinicians. Dr. Tabaac’s groundbreaking research focuses on the application of psychedelics in brain injury and stroke rehabilitation.

Dr. Tabaac was recently appointed by the Governor of Nevada to serve as a member of the state’s Psychedelic Medicines Working Group, which provides expertise and testimony relating to the therapeutic use of entheogens.

As the host of The Zero Hour Podcast, he engages with leading experts in psychedelic research. His commitment to advancing the field was further highlighted in his 2022 TEDx talk at UCLA, “Mental Health Meets Psychedelics.”

“Joining Rose Hill’s advisory team presents an exciting opportunity to further explore the potential of psilocybin in neurological recovery,” said Dr. Tabaac.

“The company’s commitment to ethical cultivation and research aligns perfectly with my vision for advancing patient care through innovative therapies. I’m eager to bring my expertise to Rose Hill and contribute to the evolving landscape of psychedelic medicine.”

Charles Lazarus

Chief Executive Office

Mr. Lazarus boasts over 16 years of extensive expertise in psilocybin and cannabis, focusing on genetic development, cultivation, extraction, and operations logistics. Notably, he recently achieved a milestone by cultivating and delivering the largest legal shipment of premium psilocybin globally.

As an accomplished owner/operator, Mr. Lazarus has successfully managed multiple farming and harvesting businesses, earning commendations for his unwavering commitment to quality and impressive output volumes. Since 2015, he has been actively involved in producing proprietary psilocybin genetics and cultivation solutions tailored for the Jamaican market and large research and development clients.

His contributions span various aspects, including genetic development, cultivation, extraction, harvest, and logistics. Additionally, Mr. Lazarus owned and operated Island Fresh Ltd., a venture that played a pivotal role in exporting fresh fruit, ground provisions, and promoting brand Jamaica to the English market. Under his leadership, Island Fresh Ltd. achieved the highest volume from Jamaica for three consecutive years.

Mr. Lazarus’s extensive experience also includes serving as the Harvest Manager for cannabis grow operations in California from 2013 to 2017, further solidifying his comprehensive knowledge in the cannabis industry.